Table 4. Five-year BCSS outcomes by CS, PS, CPS+EG, Neo-Bioscore, and CPS+EGHlow staging system in whole population*.
| CS | BCSS (95% CI) |
PS | BCSS (95% CI) |
CPS+EG | BCSS (95% CI) |
Neo-Bioscore | BCSS (95% CI) |
CPS+EGHlow | BCSS (95% CI) |
| BCSS, breast cancer-specific survival; CS, clinical stage; PS, pathologic stage; 95% CI, 95% confidence interval. *, 1,891 patients with mature follow-up information were involved in survival analysis. | |||||||||
| I (N=121) | 100 | 0 (N=497) | 97.9 (95.4−100) | 0 (N=199) | 94.1 (83.6−100) | 0 (N=84) | 100 | 0 (N=82) | 100 |
| IIA (N=561) | 96.1 (92.8−99.4) | I (N=337) | 97.9 (95.8−100) | 1 (N=528) | 98.0 (95.7−100) | 1 (N=325) | 96.9 (91.0−100) | 1 (N=300) | 97.7 (90.5−100) |
| IIB (N=821) | 93.3 (90.4−96.3) | IIA (N=504) | 92.3 (88.2−96.7) | 2 (N=627) | 97.0 (94.9−99.1) | 2 (N=503) | 97.7 (95.4−100) | 2 (N=436) | 95.6 (92.4−99.0) |
| IIIA (N=313) | 84.9 (79.3−90.8) | IIB (N=159) | 89.9 (82.7−97.8) | 3 (N=472) | 84.1 (79.4−89.0) | 3 (N=576) | 95.3 (92.8−97.9) | 3 (N=528) | 94.3 (91.0−97.8) |
| IIIB (N=110) | 80.0 (69.1−92.7) | IIIA (N=352) | 87.3 (81.9−93.1) | 4 (N=219) | 79.6 (72.4−87.6) | 4 (N=409) | 84.2 (79.4−89.3) | 4 (N=450) | 88.0 (83.3−93.0) |
| IIIC (N=215) | 83.3 (76.3−91.0) | IIIB (N=48) | 96.3 (89.4−100) | 5 (N=77) | 83.8 (73.4−95.8) | 5 (N=169) | 73.3 (64.5−83.4) | 5 (N=232) | 76.3 (68.6−84.7) |
| IIIC (N=244) | 73.7 (66.0−82.2) | 6 (N=19) | 31.2 (15.6−86.0) | 6 (N=75) | 42.9 (10.3−87.7) | 6−8 (N=113) | 30.4 (9.3−81.1) | ||